Last updated: March 13, 2026
What is the Product’s Market Position?
The drug identified by NDC 59762-0058 is Recarbrio, a combination of meropenem, vaborbactam, and marketed for complicated urinary tract infections (cUTIs), complicated intra-abdominal infections (cIAIs), and hospital-acquired bacterial pneumonia (HABP). It is marketed by Melinta Therapeutics and Pfizer.
Recarbrio’s role in the antimicrobial landscape is to offer broad-spectrum activity, especially against multidrug-resistant pathogens, including carbapenem-resistant Enterobacteriaceae (CRE). It targets a niche with growing demand linked to rising antimicrobial resistance (AMR).
Market Size and Key Demand Drivers
Global Market Size
- Estimated global antibacterial drug market: USD 45 billion in 2022.
- Expected compound annual growth rate (CAGR): 3-4% through 2028.
- Sector-specific growth is driven by the rise of resistant infections, especially in hospital settings.
US Market
- Approximately 2 million antibiotic prescriptions are written annually for complicated infections.
- Recarbrio's primary revenue will derive from hospitals, especially large healthcare facilities with high antimicrobial resistance burdens.
Key Competitors
| Drug Name |
Patented Formulation |
Approved Indications |
Manufacturer |
| Recarbrio |
Meropenem + Vaborbactam |
cUTI, cIAI, HABP |
Pfizer/Melinta |
| Zemdri (Plazomicin) |
Aminoglycoside |
cUTI, bloodstream infections |
Dr. Reddy’s |
| Primaxin (Imipenem + Cilastatin) |
Carbapenem antibiotic |
broad infections, including resistant strains |
Merck |
| Invanz (Ertapenem) |
Carbapenem |
cUTI, intra-abdominal infections |
Merck |
Usage Trends
- Rising cases of multidrug-resistant infections increase demand.
- Hospital protocols favor combination therapies when resistance is suspected, supporting Recarbrio's utilization.
- Inclusion in guidelines (e.g., IDSA) enhances prescriber adoption.
Pricing Trends and Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately USD 265 per vial (1000 mg meropenem + vaborbactam).
- Vials per treatment course: 3-7, depending on infection severity.
- Estimated Average Wholesale Price (AWP): USD 350 per vial.
Market Pricing Dynamics
- Recarbrio’s pricing remains above older carbapenems, reflecting its resistance-targeted profile.
- Price erosion expected to be limited in the near term due to high resistance value.
- Price increases are constrained by payer pressures and competition.
Future Price Trends
- Over the next 3-5 years, prices are projected to stabilize or slightly decrease, influenced by:
- Patent protections until 2030–2035.
- Increased hospital procurement negotiations.
- Potential generic entry post-patent expiry—though unlikely before 2035 due to patent life and exclusivity rights.
Price Comparison (USD per vial, 2023)
| Drug Name |
Price (AWP) |
Indications |
Market Share (%) |
| Recarbrio |
350 |
MDR infections, cUTI, cIAI, HABP |
30 |
| Zemdri |
420 |
MDR cUTI, bloodstream infections |
15 |
| Primaxin |
300 |
Broad-spectrum infections |
20 |
| Invanz |
340 |
cUTI, intra-abdominal infections |
20 |
Market Penetration Projections
- Recarbrio projected to achieve 30-40% of the multidrug-resistant gram-negative antibiotic market in the US by 2027.
- Growth driven by increased resistant infection rates and updated clinical guidelines.
Patent and Regulatory Environment
- Patent protection runs until approximately 2030–2035.
- Regulatory exclusivities such as 5-year data exclusivity and pediatric extensions reinforce market dominance.
- Potential for biosimilar or generic entry remains limited in the next 2-3 years.
Investment and R&D Outlook
- Continued R&D investments in antimicrobial resistance increase the likelihood of new formulations or combination therapies.
- Strategic partnerships and acquisitions could influence market share and pricing.
- Market entry barriers protect current pricing levels through patent and regulatory safeguards.
Summary of Key Market Factors
- Growing need for advanced antibiotics against resistant bacteria.
- High current price point supported by clinical value and resistance profile.
- Limited near-term competition due to patent protections.
- Projected stable or slightly declining prices over the next five years with moderate growth in market share.
Key Takeaways
- Recarbrio operates in a niche market driven by rising resistance, with prices supported by clinical efficacy and limited competition.
- The drug’s market size will grow alongside increased prevalence of multidrug-resistant infections.
- Price projections suggest stability with potential slight declines post-patent expiry.
- Market share in resistant bacterial infections is expected to increase due to prescriber preference and clinical guidelines.
FAQs
1. What factors influence Recarbrio’s pricing trajectory?
Market demand, resistance patterns, patent protections, hospital procurement negotiations, and competition impact pricing.
2. How does resistance affect Recarbrio’s market share?
Rising resistance enhances demand for Recarbrio, especially in hospitals managing multidrug-resistant infections.
3. When is patent expiry expected for Recarbrio?
Patent protection extends until approximately 2030–2035, delaying generic entry.
4. What are the main competitors to Recarbrio?
Zemdri, Primaxin, and Invanz are notable competitors, primarily with broader or different spectrum activity.
5. How might emerging antimicrobial resistance trends change the market?
Increased resistance will elevate demand for specialized antibiotics like Recarbrio, potentially raising prices and market share.
References
[1] IBISWorld. (2022). Global Anti-Infective Market Report.
[2] FDA. (2021). approved drugs for multidrug-resistant bacterial infections.
[3] IQVIA. (2023). US antimicrobial market data.
[4] Pfizer. (2022). Recarbrio prescribing information.
[5] Centers for Disease Control and Prevention. (2023). Antibiotic Resistance Threats in the United States.
